GeneOne Life Science, Inc. (KRX:011000)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,260.00
-35.00 (-1.53%)
At close: Jul 24, 2025, 3:30 PM KST
-1.53%
Market Cap194.40B
Revenue (ttm)37.19B
Net Income (ttm)-47.89B
Shares Out84.71M
EPS (ttm)-600.40
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume325,580
Average Volume573,295
Open2,305.00
Previous Close2,295.00
Day's Range2,250.00 - 2,340.00
52-Week Range1,830.00 - 4,735.00
Beta0.80
RSI38.45
Earnings DateAug 14, 2025

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 42
Stock Exchange Korea Stock Exchange
Ticker Symbol 011000
Full Company Profile

Financial Performance

In 2024, GeneOne Life Science's revenue was 35.72 billion, a decrease of -11.15% compared to the previous year's 40.20 billion. Losses were -48.54 billion, -37.59% less than in 2023.

Financial Statements

News

There is no news available yet.